Afternoon Symposium - Oncofertility II - Female

Date:October 21, 2014

Time:4:15 pm - 6:15 pm

Location:HCC316 - Hawaii Convention Center

Presenters

Mitchell P. Rosen, M.D. (Chair), University of California San Francisco Center for Reproductive Health

Kutluk Oktay, M.D., New York Medical College

Janine Mash, M.S., University of California, San Francisco

Richard A. Anderson, M.D., Ph.D., University of Edinburgh

Supporters

Supported by an educational grant from Ferring Pharmaceuticals, Inc.

Needs Assessment and Description
Many young adult women diagnosed with cancer will have treatment that can reduce reproductive lifespan, although many don’t learn this fact before their treatment commences. Yet, obtaining information about the risk of treatment-associated infertility and premature menopause is a top concern for patients. Our understanding of how cancer treatment affects ovarian reserve and how we manage patients undergoing fertility preservation continues to evolve. This symposium will provide reproductive endocrinologists and oncologists with the most current information on how to counsel and individualize the potential loss in reproductive capacity. Faculty will also discuss current treatments for fertility preservation and focus on additional factors that should be considered when caring for these patients. 

Learning Objectives
At the conclusion of this session, participants should be able to: 

  1. Counsel patients regarding the risk of gonadal failure after cancer treatments. 
  2. Describe how to optimally manage/stimulate patients undergoing fertility preservation. 
  3. Determine a plan for patients with inherited conditions who may desire preimplantation genetic diagnosis. 
ACGME Competency
Patient Care
Interpersonal and Communication Skills 

TEST QUESTION
Which of the following would be least accurate when managing cancer patients who are considering fertility preservation?
a. An assessment of ovarian reserve is required at the initial consultation.
b. Patients must wait until their menses begin to start ovarian stimulation for the purpose of egg/embryo cryopreservation.
c. Genetic evaluation is required to determine the genetic predisposition of their disease.
d. If menses resume after chemotherapy, early menopause is inversely associated with the age of the patient.

ASRM MEMBERSHIP

View Details
Learn More | Join | Renew
Back to Top